NIH Reporter #11307042

NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patients with Retinitis Pigmentosa

A NIH-funded Phase-3 clinical trial evaluating N-acetylcysteine for retinitis pigmentosa, focusing on preserving vision over 45 months.

Description

This is a clinical trial for retinitis pigmentosa using N-acetylcysteine. The trial aims to assess the efficacy of NAC in preserving cone cells and preventing severe visual disability. The study involves spectral domain-optical coherence tomography, microperimetry, and whole genome sequencing. The trial is multicenter, randomized, double-masked, and placebo-controlled. The primary outcome is the change in ellipsoid zone width over 45 months. The project is funded by the NIH, with an award amount of $344,858. The project is associated with Johns Hopkins University.

View original record